Antibody-drug Conjugates

DBCAT005781Pharmacologic class

A DrugBank category of 23 drugs. 12 of them are approved.

Drugs: Anetumab ravtansine
Belantamab mafodotin
Brentuximab vedotin
Cantuzumab mertansine
Cantuzumab ravtansine
Coltuximab ravtansine
Datopotamab deruxtecan
Disitamab vedotin
Enapotamab vedotin
Enfortumab vedotin
Farletuzumab ecteribulin
Gemtuzumab ozogamicin
Indatuximab ravtansine
Indusatumab vedotin
Inotuzumab ozogamicin
Loncastuximab tesirine
Lorvotuzumab mertansine
Mirvetuximab soravtansine
Polatuzumab vedotin
Sacituzumab govitecan
Tamrintamab pamozirine
Trastuzumab deruxtecan
Trastuzumab emtansine

What you can answer from here — as of November 16, 2022

23DrugsEach linked to its full drug card

Listed above

21Drug targetsEvery drug–target pair in the class, with bond type

93Marketed productsAcross the regions we cover, with dosage forms and routes

3Routes of administrationHow the drugs in this class are given

Which targets do Antibody-drug Conjugates share, and which companies have late-stage candidates in this class?

Create a free account or log in to explore the full data card.